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During retroviral infection, viral capsids are subject to
restriction by the cellular factor TRIM5a. Here, we
show that dendritic cells (DCs) derived from human
and non-human primate species lack efficient
TRIM5a-mediated retroviral restriction. In DCs,
endogenous TRIM5a accumulates in nuclear bodies
(NB) that partly co-localize with Cajal bodies in a
SUMOylation-dependent manner. Nuclear seques-
tration of TRIM5a allowed potent induction of type I
interferon (IFN) responses during infection, mediated
by sensing of reverse transcribed DNA by cGAS.
Overexpression of TRIM5a or treatment with the
SUMOylation inhibitor ginkgolic acid (GA) resulted in
enforced cytoplasmic TRIM5a expression and res-
tored efficient viral restriction but abrogated type I
IFN production following infection. Our results sug-
gest that there is an evolutionary trade-off specific
to DCs in which restriction is minimized to maximize
sensing. TRIM5a regulation via SUMOylation-depen-
dentnuclear sequestrationadds toourunderstanding
of how restriction factors are regulated.
INTRODUCTION
After entry in target cells, retroviral capsids are subject to
host restriction by the ‘‘alpha’’ spliced variant of tripartite motif
protein 5 (TRIM5a) (Stremlau et al., 2004). Restriction operates
by direct recognition of the viral capsid in the cytoplasm, leading
to a premature and accelerated uncoating and to abortive
infection (Stremlau et al., 2006). TRIM5a proteins restrict
retroviruses in a species-specific manner and thus constitute
an effective barrier to cross-species transmissions of retrovi-
ruses. For instance, rhesus macaque (RM) TRIM5a restrictsCHIV-1, SIVagm, and N-MLV, but not SIVmac, whereas human
TRIM5a can block N-MLV and equine infectious anemia virus
(EIAV), but is less effective against HIV-1 (Bieniasz, 2004; Song
et al., 2005).
TRIM5a-mediated restriction was identified in a number
of macaque primary cells and cell lines (LLC-MK2, FRhK-4,
FrHL-2, Rh.F and RM primary lung fibroblasts) (Besnier et al.,
2002; Cowan et al., 2002; M€unk et al., 2002; Stremlau et al.,
2004; Yap et al., 2004). However, while RM T lymphocytes effi-
ciently block HIV-1 infection, we have previously shown that
RM dendritic cells (DCs) lack TRIM5a-mediated restriction and
are permissive to HIV-1 infection (Arhel et al., 2008). We further
showed that TRIM5a RNA levels are normal in DCs and there
is no detectable increase in the competitive inhibitor TRIM5g.
These findings suggest that the endogenous TRIM5a protein is
likely to be dysfunctional, a possibility supported by the finding
that the overexpression of RM TRIM5a in DCs restores restric-
tion (Arhel et al., 2008).
Recent work proposed that TRIM5a restriction may be modu-
lated by the small ubiquitin-related modifier (SUMO) machinery
(Arriagada et al., 2011; Dutrieux et al., 2015; Lukic et al., 2013;
Nepveu-Traversy and Berthoux, 2014). The human SUMO family
consists of four members, SUMO1 to SUMO4. SUMO can either
be directly conjugated to protein substrates by covalent addition
of a SUMOmoiety to a lysine residuewithin theJKxE consensus
sequence (where J is a large hydrophobic residue and x any
amino acid) (Sampson et al., 2001), or can interact non-cova-
lently with target proteins through SUMO-interaction motifs
(SIMs) (Hecker et al., 2006;Minty et al., 2000). Many viral proteins
are SUMOylated or influence the SUMOylation of cellular pro-
teins, and the infection of some viruses is dependent on path-
ways that are regulated by SUMOylation (Everett et al., 2013).
SUMO1 overexpression enhances restriction of N-MLV and
HIV-1 by human and RM TRIM5a, respectively, while knock-
down of SUMO1 or the Ubc9 E2 SUMO-conjugating enzyme re-
duces HIV-1 restriction by RM TRIM5a (Arriagada et al., 2011;
Dutrieux et al., 2015; Lukic et al., 2013). We recently showedell Reports 14, 355–369, January 12, 2016 ª2016 The Authors 355
Figure 1. Lack of TRIM5a-Mediated Restriction in Human and Non-human Primate Myeloid DCs
(A–C) PBLs and DCs from (A) rhesus macaque, (B) human, and (C) African green monkey were transduced at MOI 5, ± nevirapine (5 mM), tenofovir disoproxil
fumarate (TDF, 100 mM), heat-treated, or treated with a specific siRNA against human and RM TRIM5a (siHM3). Representative flow cytometry charts at 3 dpt are
(legend continued on next page)
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that human and RM TRIM5a are substrates for SUMO modifica-
tion in vitro and in cellulo, and the putative SUMO conjugation
consensus site at residue K10 is the main site for SUMO modifi-
cation (Dutrieux et al., 2015). However, although K10R point mu-
tants abrogated SUMOylation at this position, TRIM5a antiviral
activity was not impaired, arguing that non-covalent interaction
with SUMO or SUMO-modified proteins rather than direct
SUMOylation of TRIM5a might be responsible for TRIM5a re-
striction. Three SIMs that are able to bind SUMO1were identified
within the PRYSPRY domain necessary for capsid recognition
and are shown to contribute to the ability of human TRIM5a to
restrict N-MLV infection (Arriagada et al., 2011; Lukic et al.,
2013). Given that the MLV capsid (CA) was shown to undergo
SUMO1 conjugation (Yueh et al., 2006), this suggests that hu-
man TRIM5a might interact with SUMOylated MLV CA via
SIMs within the PRYSPRY domain. However, two of the three
SIMs in RM TRIM5a are reportedly buried internally within
the PRYSPRY domain and are therefore unlikely to mediate
SUMO-SIM interactions (Brandariz-Nun˜ez et al., 2013).
The aim of this studywas to define themechanism responsible
for the lack of TRIM5a function in DCs and to clarify the effects on
viral immune sensing by these potent accessory cells. We first
show that absence of TRIM5a restriction is observed in DCs
from all tested human and non-human primates, pointing to a
common trait of humans and old world monkeys. Endogenous
TRIM5a in DCs was found to be sequestered in the nucleus
within NB that co-localize with Cajal bodies, a phenotype that
was reversed upon treatment with ginkgolic acid (GA), an inhib-
itor of the E1 SUMO activating enzyme. Finally, induced cyto-
plasmic localization of TRIM5a in DCs by its overexpression or
by GA treatment restored restriction and abrogated type I IFN
production following retroviral infection. Together, our data
show that TRIM5a is unable to restrict incoming retroviruses in
DCs because it is absent from the cytoplasm. The resulting un-
hampered retroviral infection triggers innate sensing by host
cell sensors and robust type I IFN production, suggesting that
the lack of TRIM5a restriction in DCs is an anti-viral mechanism
that has evolved to promote immune responses necessary to
control viral spread in the infected host.
RESULTS
Human and Non-human Primate DCs Lack
TRIM5a-Mediated Restriction
We previously showed that RM (Macaca mulatta) DCs, contrary
to all other tested RMcells (Arhel et al., 2008; Besnier et al., 2002;
Cowan et al., 2002; M€unk et al., 2002; Stremlau et al., 2004; Yap
et al., 2004), are permissive to HIV-1 infection, indicating an
absence of functional TRIM5a-mediated restriction in this cell
type (Arhel et al., 2008). Given that immature DCs are highly
phagocytic, we carried out retroviral transductions in the pres-
ence of a reverse transcription inhibitor to ascertain whether up-shown left, while graphs show the mean of three independent experiments with lo
n = 2) and different vector batches.
(D) PBLs and DCs from cynomolgus macaque (n = 2), human (n = 3) and pigtailed
Graphs show GFP expression 3 dpt (3 independent experiments ± SD).
See also Figure S1.
Ctake might be the result of non-specific pseudo-transduction.
RM peripheral blood lymphocytes (PBLs) andmonocyte-derived
DCs were characterized with phenotypic markers (Figure S1A)
and transduced with either SIVmac (not restricted) or HIV-1
(restricted). RM PBLs were not permissive to HIV-1, and treat-
ment with a specific TRIM5a small interfering RNA (siRNA)
restored transduction, confirming that TRIM5a is responsible
for restriction in these cells (Figure 1A). In contrast, RM DCs
were equally permissive to SIVmac and HIV-1, indicating an
absence of efficient TRIM5a restriction in DCs. HIV-1 infection
of RM DCs was also observed using R5-tropic HIV-1 virus (Fig-
ure S1B). Treatment with nevirapine (Nev) reduced HIV-1 in-
fection to levels similar to those seen in uninfected samples,
validating that HIV-1 infection of RM DCs resulted in bona fide
productive transduction events (Figure 1A).
To determine whether the absence of TRIM5a restriction in
DCs is a common phenomenon, human PBLs and DCs were
transduced with either HIV-1 (not restricted) or EIAV (restricted)
vectors (Figure 1B). DCs were 2-fold less permissive than
PBLs to HIV-1 infection (12.0% ± 6.9% versus 24.1% ± 8.7% in-
fected cells, n = 4), as reported in the literature (Berger et al.,
2011; Laguette et al., 2011). As expected, human PBLs were re-
fractory to EIAV infection (0.9% ± 0.3% infected cells) and
knockdown of TRIM5a in these cells restored transduction,
confirming that restriction is mediated by TRIM5a. Human
DCs, on the other hand, were efficiently transduced with EIAV
(28.7% ± 3.8%), pointing to absence of restriction. Infection in
the presence of tenofovir (TDF), which blocks both HIV-1 and
EIAV reverse transcription (Figure S1C), reduced infection to
levels comparable to uninfected samples (0.5% and 1.6% for
PBLs and DCs, respectively, Figure 1B).
Similarly, African green monkeys (AGM, sabaeus species)
PBLs were found to be non-permissive to HIV-1 transduction
with <1%GFP-positive PBLs and weakly permissive to SIVmac,
with8% transduction. In contrast, >30%Chlorocebus sabaeus
DCswere efficiently transduced by HIV-1 and20% by SIVmac,
indicating an absence of efficient TRIM5a restriction in AGMDCs
(Figure 1C).
Since restriction by TRIM5a is saturable, the addition of suffi-
cient quantities of virus-like particles overcomes its activity. To
ensure that the transduction of DCs did not saturate TRIM5a
activity, we performed dose-response studies. PBLs and DCs
from cynomolgus macaques (CM) (Macaca fascicularis), whose
TRIM5a restricts HIV-1 but not SIVmac, were infected with
increasing MOI from 0.5 to 25. Cells from pigtailed macaques
(PTM) (Macaca nemestrina), which, in the place of TRIM5a, ex-
press a TRIMCyp fusion protein that cannot bind to or restrict
HIV-1 (Brennan et al., 2008; Liao et al., 2007; Newman et al.,
2008; Virgen et al., 2008), and cells from human donors were
included as controls. PBLs from all three species were per-
missive to SIVmac transduction (Figure 1D). However, as ex-
pected, CM PBLs were poorly permissive to HIV-1 transductiong10 scale ± SD using different primate donors (RM, n = 2; human, n = 4; AGM,
macaque (n = 3) were transduced with increasing MOI ranging from 0.5 to 50.
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Figure 2. Endogenous TRIM5a Is Cytoplasmic in PBLs and Forms Nuclear Bodies in Human and RM DCs
(A) Endogenous TRIM5a localization in human and RM PBLs and DCs. Insets show higher magnification images for each sample. Scale bars represent 10 mm.
(B) TRIM5a (green) and Golgi marker GM-130 (red) co-localization in human PBLs and DCs. Scale bar represents 5 mm.
(C) TRIM5a protein levels from whole cell extracts (RM and human) and following fractionation (human). Left-hand graph shows quantification from six different
samples (ImageJ).
See also Figure S2.compared with PTM and human PBLs, even at high MOI, indi-
cating efficient restriction of HIV-1. In contrast, CM DCs were
as permissive to HIV-1 infection as PTM DCs and more permis-
sive than human DCs, even at a MOI as low as 0.5 (Figure 1D).
Thus, our results demonstrate a lack of efficient TRIM5a-me-
diated restriction in DCs from rhesus, cynomolgus, and pigtailed
macaques, in humans, and in African green monkeys, suggest-
ing that this phenomenon is a widespread trait of primate DCs.
Infection of DCswas dependent on efficient reverse transcription
and was also observed at low MOI, indicating that it was not a
result of pseudotransduction (non-specific uptake of GFP pro-
tein) or saturation of the TRIM5a restriction factor.
Endogenous TRIM5a Localizes to Nuclear Bodies in DCs
TRIM5a proteins from humans and RM have been reported to
shuttle between the cytoplasm and the nucleus (Diaz-Griffero
et al., 2011). We therefore hypothesized that TRIM5a might be
mislocalized in DCs and thus unable to interact with incoming
cytoplasmic retroviral cores. To test this hypothesis, we used a
rabbit polyclonal antibody raised against a C-terminal fragment
of TRIM5a (Zhang et al., 2008) to detect endogenous TRIM5a.
Reactivity against rhesus TRIM5a (TRIM5arh) was previously es-
tablished by western blotting (Zhang et al., 2008), and we
confirmed that it also recognizes endogenous human TRIM5a
(TRIM5ahu) (Figure S2A). Similarly to commercial antibodies,358 Cell Reports 14, 355–369, January 12, 2016 ª2016 The Authorsthe rabbit TRIM5a antibody used for this study recognizes higher
molecular weight bands that likely correspond to TRIM5a multi-
mers (Li et al., 2011; Nepveu-Traversy et al., 2009). Specific
TRIM5a knockdown was associated with a marked decrease
in the TRIM5a signal detected by immunofluorescence (Fig-
ure S2B). Conversely, transduction of MDTF cells that do not
encode a TRIM5 ortholog (reviewed in Lee and KewalRamani,
2004) with TRIM5arh-HA or TRIM5ahu-HA led to positive TRIM5a
labeling in HA-positive cells, while negative cells showed mini-
mal background staining (Figure S2C).
PBLs and DCs from human and RM donors were labeled with
the TRIM5a-specific antibody to assess endogenous localiza-
tion in these cells (Figure 2A). Whereas TRIM5a localized mainly
in the cytoplasm of PBLs, it aggregated within the nucleus of DC
in structures reminiscent of NB, a phenotype that was not
observed in PBLs. Although some cytoplasmic signal was also
detected in DCs, the majority co-localized with the Golgi marker
GM-130 (Figure 2B). Golgi-localized TRIM5a, which may corre-
spond to a step in TRIM5a proteasome-independent degrada-
tion (Sastri and Campbell, 2011), was also observed in PBLs.
In contrast, dense nuclear aggregates were never observed in
PBLs. Whole-cell extracts revealed no difference in total levels
of TRIM5a between PBLs and DCs, but subcellular fractionation
confirmed the differences in subcellular localization observed
by microscopy (Figure 2C). Given that TRIM5a restriction is
operational in PBLs but not DCs, we hypothesized that the accu-
mulation of TRIM5a in structures resembling NB in DCs might
account for its lack of antiretroviral activity.
DC Nuclear TRIM5a Aggregates in Cajal Bodies but Not
in PML-NB
Previous work showed that exogenously expressed TRIM5a in
HeLa cells can be induced to co-localize with PML-NB by
blocking CRM1-dependent protein nuclear export with lepto-
mycin B treatment (LMB) (Diaz-Griffero et al., 2011). We there-
fore tested whether nuclear TRIM5a aggregates co-localize
with PML-NB. In PBLs, TRIM5a is mainly cytoplasmic and no
co-localization with PML-NB was detected (Figure 3A). In
DCs, TRIM5a NB and PML-NB were both readily observed,
but the signals did not overlap (Manders’ coefficient of co-
localization M < 0.1). Treatment with IFNa, previously shown
to enhance TRIM5a and PML expression (Carthagena et al.,
2008; Sakuma et al., 2007), increased the number and size
of PML-NB, as previously described (Chelbi-Alix et al., 1995),
but did not induce co-localization between TRIM5a and
PML-NB. LMB treatment, shown to trap TRIM5a in the nu-
cleus (Diaz-Griffero et al., 2011), induced diffuse nuclear
accumulation of TRIM5a in PBLs, but not co-localization with
PML-NB.
Next, we tested for TRIM5a co-localization with another nu-
clear body, Cajal bodies, using the marker p80 coilin to identify
these subnuclear structures (Figure 3B). In DCs, TRIM5a NB
were found to partially co-localize with coilin (M 0.3), indi-
cating that in DCs 30% of TRIM5a might be trapped in Cajal
bodies. This was observed both in human and RM DCs and
was not further induced by LMB treatment (Figure 3B). To
confirm the interaction of endogenous TRIM5a with Cajal
bodies, we performed a Duolink in situ proximity ligation assay
(Figure 3C). In PBLs, signal detection was low (0.27 ± 0.06
spots/cell) indicating a lack of proximity between TRIM5a and
coilin. In DCs, however, signals of proximity were about seven
times more frequent (1.86 ± 0.35 spots/cell). Given that the
number of Cajal bodies detected in DCs is one to five per
nucleus, this result is concordant with the co-localization of
TRIM5a with Cajal bodies.
Mislocalization of TRIM5a in DCs Accounts for Lack of
Restriction
We previously showed that overexpression of TRIM5arh in RM
DCs restores efficient restriction of HIV-1 infection (Arhel et al.,
2008). We therefore tested the effect of TRIM5a overexpression
on its localization. Human DCs were either labeled with TRIM5a
antibody to reveal endogenous protein, or transducedwith a len-
tiviral vector coding for mRFP-TRIM5ahu fusion protein. While
endogenous TRIM5a formed nuclear aggregates in DCs, its
overexpression resulted in its accumulation as dense cyto-
plasmic aggregates, characteristic of cytoplasmic bodies as
previously reported (Stremlau et al., 2004) (Figure 4A). Control
or TRIM5a-overexpressing human DCs were challenged with
EIAV and infection was assessed by flow cytometry at 48 hr
post-infection (hpi) (Figure 4B). Forced cytoplasmic expression
of TRIM5a by overexpression restored restriction against EIAV
in human DCs, suggesting that TRIM5a nuclear localization inCDCs accounts for the lack of efficient restriction. To confirm
this, TRIM5arh was fused at its N terminus to the Cajal body tar-
geting domain (CBD) of human coilin (Figure 4C). P4-CCR5 cells
were transduced with TRIP-TRIM5arh or TRIP-Coilin-TRIM5arh
and challenged with HIV-1. Infection was efficiently restricted
by TRIM5a but forced nuclear targeting abrogated restriction,
confirming that mislocalization of TRIM5a accounts for the lack
of restriction.
TRIM5a Localizes to Cajal Bodies in a SUMOylation-
Dependent Manner in DCs
Recent work showed that human and RMTRIM5a are substrates
for SUMO modification (Dutrieux et al., 2015), and that putative
SIM domains in TRIM5a may mediate interaction with SUMO-
modified proteins (Arriagada et al., 2011). SUMO modification
has been shown to modulate sub-nuclear localization and func-
tion of TRIM19/PML (M€uller et al., 1998). We therefore examined
whether SUMOmodificationmight account for TRIM5a accumu-
lation in NB of DCs. Human PBLs and DCs were treated with 10
and 100 mM GA for 24 hr and labeled for endogenous TRIM5a
and either PML or coilin. GA treatment did not induce TRIM5a
co-localization with PML in either cell type (Figure 4D). Similarly,
no co-localization between TRIM5a and coilin was detected in
PBLs and this was not altered following GA treatment. In DCs,
however, GA treatment led to a dose-dependent reduction of
TRIM5a co-localization with coilin, without reducing the number
of Cajal bodies per cell. Pre-treatment with 10 mM GA led to a
5-fold decrease in TRIM5a/coilin co-localization, and co-locali-
zation was abolished following treatment with 100 mMGA. Given
the obtained Manders’ coefficients, we estimate that approxi-
mately one-third of nuclear TRIM5a is found associated with
Cajal bodies in DCs and that this is dependent on SUMO modi-
fication. Localization of TRIM5a in Golgi was not sensitive to GA
treatment in either DCs or PBLs, indicating that it is unlikely to
contribute to the SUMOylation-dependent functional inactiva-
tion of TRIM5a in DCs.
Given that inhibition of SUMOylation counteracts TRIM5a nu-
clear localization in DCs, we next tested whether inhibition of
SUMOylation restored TRIM5a restriction in DCs. Human DCs
were treated with 100 mM GA for 24 hr and infected with EIAV.
Untreated human DCs were permissive to EIAV, whereas GA
treatment restored efficient restriction, leading to a 3- to 8-fold
reduction in infectivity in three independent experiments
(Figure 4E), suggesting that SUMOylation-dependent nuclear
sequestration of TRIM5a accounts for the observed lack of re-
striction in DCs. To determine whether GA-induced restriction
is TRIM5a-dependent, we performed GA treatment in the pres-
ence of siRNAs targeting TRIM5a. Twenty-four hours prior to
GA treatment, human DCs were DOTAP transfected with two
different siRNAs targeting either TRIM5a or Luc and then trans-
duced with EIAV (Figure 4F). GA treatment induced strong anti-
EIAV restriction in DCs, and this phenotype was reversed by
TRIM5a knockdown, indicating that GA-induced restriction in
DCs is TRIM5a-dependent. Further exploration is required to
confirm this phenotype using replicative virus, however, no repli-
cative EIAV was available at the time of the study. Together, our
results show that the lack of restriction in DCs is explained by
the SUMOylation-dependent re-localization of TRIM5a to theell Reports 14, 355–369, January 12, 2016 ª2016 The Authors 359
Figure 3. Endogenous TRIM5a Co-localizes with Cajal Bodies in Human and RM DCs
(A andB) Co-localization of TRIM5awith (A) PML-NB and (B) the Cajal bodymarker Coilin in humanPBLs andDCs ± 100U IFNa for 24 hr, 5 or 50 mg/ml leptomycin
B (LMB) for 4 hr. Scale bars represent 5 mm. Co-localization was assessed using the Image J plugin Just Another Colocalization Plugin (JACoP) with threshold set
at 20 for all images in both fluorescence channels. Graph shows Manders’ coefficients for the fraction of PML-NB overlapping with TRIM5a, mean of three
independent experiments ± SEM. In total, a minimum of 50 cells were analyzed for each condition.
(C) Proximity between TRIM5a and coilin was assessed by Duolink proximity ligation assay (red dots). Graph shows the average number of spots over the number
of Hoechst-stained nuclei in eight random fields per cell type ± SEM (Photoshop CS5).
Scale bars represent 5 mm. Statistical significance was assessed by non-parametric unpaired t test (***p% 0.001; *p% 0.05; ns, non-significant).nucleus and to Cajal bodies, thereby preventing contact with
incoming retroviral capsids.
Nuclear-Sequestered TRIM5a Is DeSUMOylated
SUMO modification of human and RM TRIM5a was demon-
strated using immobilized metal affinity chromatography on ex-360 Cell Reports 14, 355–369, January 12, 2016 ª2016 The Authorstracts prepared from HeLa cells overexpressing HA-tagged
TRIM5a, Ubc9, and 6 3 His-SUMO1 (Dutrieux et al., 2015). To
assess SUMO modification of TRIM5a in primary DCs, we
were limited by the fact that TRIM5a overexpression cannot be
used, since it reverses observed phenotypes, and endogenous
TRIM5a is present in quantities that are too small for pull-down
assays to be effective. We therefore analyzed post-translational
modifications of endogenous TRIM5a by western blotting. Prep-
aration of PBLs and DCs lysates in the presence of iodoaceta-
mide (IAA), a cysteine protease inhibitor that preserves post-
translational modifications such as SUMOylation during the
preparation of cell extracts, led to an increase in the molecular
weight of the detected TRIM5a band by 15 kDa, which is sug-
gestive of a mono-SUMO modification of TRIM5a in both PBLs
and DCs (Figure 5A). Quantification revealed that the proportion
of TRIM5a-70 relative to TRIM5a-55 was greater in PBLs than
DCs, and higher molecular weight bands were also visible in
PBL extracts prepared in the presence of IAA, but less so in
DCs (Figure 5A). These findings suggest that TRIM5a may be
more SUMO1-modified in PBLs than in DCs. To confirm that
higher molecular weight bands correspond to SUMOylated
TRIM5a, IAA extracts were prepared from DCs treated or not
with GA. GA treatment reduced overall protein SUMOylation,
as observed by reduced smearing of SUMO2/3 labeling (Fig-
ure S3A) and decreased the detection of the higher molecular
TRIM5a weight bands (Figure S3B), confirming that these repre-
sent SUMO-modified forms of TRIM5a.
To investigate the compartmentalization of TRIM5a SUMOyla-
tion, we performed Duolink in situ proximity ligation assays
(PLA), using TRIM5a and SUMO1 primary antibodies, followed
by species-specific PLA probes. The results revealed close
proximity of TRIM5a with SUMO with an average of 7.1 ± 1.2
(SEM) spots per cell in PBLs, compared with 2.2 ± 0.4 spots
per cell in DCs, pointing to reduced TRIM5a-SUMO interactions
in DCs (Figure 5B). Treatment with ginkgolic acid (GA), a small
molecule inhibitor of SUMO modification that blocks formation
of the E1-SUMO intermediate (Fukuda et al., 2009), induced a
dose-dependent reduction in TRIM5a-SUMO1 proximity sig-
nals, suggesting that endogenous TRIM5a is conjugated by
SUMO1 or interacts with SUMOylated proteins in PBLs and
DCs. TRIM5a-SUMO1 signals were observed both in the cyto-
plasm and nucleus, indicating that SUMO-modified TRIM5a
can shuttle in and out of the nucleus. However, nuclear signals
were rare in DCs (0.8 ± 0.1 spots per nucleus versus 4.8 ± 1.4
in PBLs), suggesting that nuclear-localized TRIM5a no longer as-
sociates with SUMO1 in DCs. To test this, we co-labeled TRIM5a
and SUMO1 in human DCs (Figure 5C). Both SUMO1 and
TRIM5a strongly localized to the nucleus, but the two did not
co-localize, indicating that nuclear TRIM5a does not associate
with SUMO1 in DCs.
To confirm these observations, we analyzed TRIM5a post-
translational modifications in both nuclear and cytoplasmic frac-
tions by western blotting. Cytoplasmic and nuclear fractions
from human PBLs or DCs were prepared in the presence of
IAA and loaded on gels such that for each subcellular fraction,
the lane contained lysate from equal cell equivalents (4 3 106
cells), rather than equal protein amounts (Figure 5D). High mo-
lecular weight bands were observed in PBLs and DCs cyto-
plasmic fractions, suggesting that TRIM5a is SUMOylated in
both cell types, although imaging analysis revealed that cyto-
plasmic TRIM5a is cytosolic in PBLs but Golgi-associated in
DCs (Figure 2B). Total nuclear TRIM5a was diminished in
PBLs, as in Figure 2. In DCs, nuclear TRIM5a detection was
strong, but higher molecular weight bands were consistentlyCreduced, indicating that nuclear-localized TRIM5a undergoes
deSUMOylation.
Nuclear Sequestration of TRIM5a Allows Innate Sensing
of Retroviral Infection by cGAS
Innate sensing of retroviral infections by DCs is crucial for the
establishment of an efficient immune response required for infec-
tion control. Togain insight into the relevanceof this TRIM5a regu-
lation mechanism, we askedwhether inefficient restriction in DCs
might correlate with efficient innate immune sensing.
To address this question, we induced cytoplasmic localization
of TRIM5a by overexpression of human TRIM5a in human
DCs and assessed innate sensing of retroviral infections by
measuring cytokine expression and production following infec-
tion with viruses that are either restricted by human TRIM5a
(N-MLV and EIAV) or not restricted (HIV-1). Human DCs were
transfected with the expression plasmid pLPCX-TRIM5a-HA or
pLPCX (empty vector [EV]). Transfection was preferred over len-
tiviral transduction to avoid high experimental background noise
due to sensing of the lentiviral vector. After 24 hr, DCs were
treated with 100 mM GA to inhibit SUMOylation, 100 mM TDF to
block reverse transcription, or left untreated. After a further
24 hr, DCs were transduced with HIV-1, N-MLV, or EIAV eGFP
vectors at MOI 5. DCs were harvested at 10 hpi to prepare
DNA extracts and to perform qPCR analysis of reverse transcrip-
tion products and at 24 hpi to prepare RNA extracts for qRT-PCR
quantification of TRIM5a, IFNa1, IFNb, IL6, and housekeeping
transcripts. qPCR analysis of TRIM5a transcripts confirmed an
40-fold increase in TRIM5a mRNA following overexpression
in DCs (Figure 6A). Moreover, quantification of reverse transcrip-
tion products revealed that all retroviruses underwent reverse
transcription and this was specifically blocked by the reverse
transcriptase inhibitor TDF or by heat-inactivation of vectors
prior to infection (Figure 6B). Overexpression of human TRIM5a
led to a 70%–80% reduction in reverse transcription products of
N-MLV and EIAV, but had only limited impact on HIV-1 reverse
transcription, confirming that overexpression of TRIM5a in DCs
restores efficient TRIM5a-mediated restriction of susceptible
viruses (Figures 5B and 6B). Similarly, GA treatment, which in-
duces forced re-localization of TRIM5a to the cytoplasm by
blocking its SUMOylation-dependent targeting to Cajal bodies
(Figure 4C), also reduced reverse transcription of N-MLV and
EIAV without affecting HIV-1 (Figure 6B).
To assess sensing of retroviral infection by DCs, wemeasured
cytokine expression following infection. IFNa1 and IFNb were
induced 5- to 20-fold by HIV-1, N-MLV, and EIAV infection (Fig-
ures 6C and 6D), indicating that these viruses are sensed in hu-
man DCs, as previously shown for HIV-1 (Silvin andManel, 2015;
van Montfoort et al., 2014). In contrast, IL6 expression was not
significantly induced, suggesting that the host sensor involved
likely operates via IRF-3 and not NF-kB (Figure 6E). Infection in
the presence of TDF abolished sensing (Figures 6C and 6D), at
both 24 hpi and 8 hpi, indicating that the recognized PAMP is
reverse transcribed DNA, as previously shown (Gao et al.,
2013; Lahaye et al., 2013; Rasaiyaah et al., 2013; Yoh et al.,
2015). Overexpression of human TRIM5a in the cytoplasm
strongly reduced IFNa and IFNb expression (5- to 10-fold), but
not IL6 levels, following N-MLV and EIAV infection, pointing toell Reports 14, 355–369, January 12, 2016 ª2016 The Authors 361
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Figure 5. TRIM5a deSUMOylation in DCs Nucleus Contributes to Its Nuclear Sequestration
(A) Human DCs extracts were prepared in the presence or absence of IAA (10 mM). Arrows point to TRIM5a (TRIM5a-55) and post-translationally modified
TRIM5a (TRIM5a-70). The graph shows TRIM5a-70 normalized band intensity as percentage of total (TRIM5a-55 and TRIM5a-70) for three independent ex-
periments ± SD (ImageJ).
(B) TRIM5a and SUMO1 co-localization was assessed by Duolink proximity assay (red dots) in PBLs and DCs ± 10 or 100 mMGA for 24 hr. Scale bars represent
5 mm. Graph shows the average number of spots over the number of Hoechst-stained nuclei in eight random fields per cell type ± SEM (Photoshop CS6).
Statistical significance was assessed by non-parametric unpaired t test (***p% 0.001; **p% 0.01; *p% 0.05; ns, non-significant).
(C) Lack of TRIM5a (green) and SUMO-1 (red) co-localization in human DC nuclei.
(D) Cytoplasmic and nuclear fractions from human PBLs or DCs were prepared in the presence of IAA and loaded as equal cell equivalents. Tubulin and lamin A/C
control for the purity of cytoplasmic and nuclear fractions only and should not be considered as loading control since PBLs and DCs differ substantially in tubulin
and lamin A/C levels per cell.
See also Figure S3.inefficient sensing following forced altered localization of restric-
tive TRIM5a to the cytoplasm (Figures 6C–6E). In contrast, HIV-1
sensing was not diminished by human TRIM5a overexpression,
which is concordant with the fact that TRIM5a overexpressionFigure 4. SUMOylation-Dependent Mislocalization of TRIM5a in DCs A
(A) Human DCs were labeled with anti-TRIM5a antibody (above), or transduced w
shown for each condition. Scale bar represents 10 mm.
(B) Human DCs were transduced or not with mRFP-TRIM5ahu for 2 days and infe
3 dpt are shown left, while the graph shows the mean of three independent expe
(C) RM TRIM5a was fused in frame at its amino terminus with the first 112 aa of hu
CCR5 cells transduced with TRIP-TRIM5arh, TRIP-Coilin-TRIM5arh, or untransd
challenged with HIV-1 LAI with either wild-type envelope or VSV-G. b-galactos
independent experiments carried out in triplicate ± SD.
(D) Co-localization of TRIM5a and Coilin was measured as in Figure 3B in human P
for the fraction of coilin-labeled Cajal bodies overlapping with TRIM5a, mean of th
each condition. Statistical significancewas assessed by unpaired t test (***p% 0.0
localization.
(E) Human DCs were treated or not with 100 mM GA for 24 hr and infected with E
shown left, while the graph shows the mean of three independent experiments ±
(F) Human DCs were lipofected or not with two different siRNAs targeting human
eGFP at MOI 1 (day 2). TRIM5amRNA expression on day 3 is normalized for hous
set to 1. GFP expression on day 4 is the mean of two experiments ± SD.
Cdid not reduce HIV-1 reverse transcripts (Figure 6B). The defect
in type I IFN production was confirmed by measuring levels of
type I IFN released in supernatants from infected DCs at 48 hr
post-infection using HL116 indicator cells (Figure S3C).ccounts for Lack of Restriction
ith mRFP-TRIM5ahu for 48 hr (below). Two representative confocal images are
cted with EIAV-eGFP vector at MOI 1. Representative flow cytometry charts at
riments ± SEM.
man coilin, comprising the Cajal body targeting domain (CBD) and a NLS. P4-
uced (NT) were labeled for TRIM5a for immunofluorescence detection and
idase activity at 48 hpi is shown normalized by Bradford as the mean of two
BLs and DCs ± 10 or 100 mMGA for 24 hr. Graph shows Manders’ coefficients
ree independent experiments ± SEM with a minimum of50 cells analyzed for
01 **p% 0.01 *p% 0.05; ns, non-significant). White arrows point to areas of co-
IAV-eGFP vector at MOI 1. Representative flow cytometry charts at 3 dpt are
SEM.
TRIM5a (HM1 and HM3) or control siLuc (day 0) ± 100 mMGA (day 1) and EIAV-
ekeeping transcript RPL13A (60S ribosomal protein L13a) with siLuc arbitrarily
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Figure 6. Forced Altered Localization of TRIM5a by
Overexpression of TRIM5a or Inhibition of SUMOy-
lation Reduces Type I IFN Induction following
Retroviral Infection
Human DCs were DOTAP transfected with pLPCX TRI-
M5a-HA (T5) or empty pLPCX (EV) at 1 mg DNA/0.1 3 106
DCs, or left untransfected (day 0) ± 100 mM GA or 100 mM
TDF (day 1) and infected with indicated retroviruses at MOI
5 (day 2).
(A) TRIM5a mRNA expression normalized for house-
keeping transcript RPL13A (60S ribosomal protein L13a).
NI EV cells were arbitrarily set to 1.
(B) Infection efficiency was assessed by qPCR of eGFP/
eYFP DNA in DCs extracts at 10 hpi. eGFP/eYFP signal
was normalized for housekeeping gene GAPDH. NT or EV
were arbitrarily set to 100% for each infection. Signal was
undetectable for non-infected samples.
(C–E) IFNa1 (C), IFNb (D), and IL6 (E) mRNA expression
levels were assessed by reverse transcription qPCR at
24 hpi, normalized for housekeeping transcript b2M. NI NT
cells were arbitrarily set to 1. All panels are representative
of at least three independent experiments on different
donors.
See also Figure S4.
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Similarly, the inhibition of SUMOylation by GA treatment of
DCs led to a stark reduction in IFNa and IFNb transcripts (5- to
10-fold), but not IL6, confirming that the restoration of TRIM5a
restriction in DCs by blocking the SUMOmachinery reduces effi-
cient sensing of retroviral infection (Figures 6C–6E). Combining
GA treatment with TRIM5a overexpression generally further
accentuated the block in type I IFN expression following
N-MLV or EIAV infection. On the other hand, GA treatment did
not affect sensing of HIV-1, indicating that non-specific effects
of GA treatment other than TRIM5a regulation are unlikely.
TRIM5a has been reported to contribute to innate immune
sensing of HIV-1 infection (Pertel et al., 2011). To determine
whether endogenous TRIM5a contributes to viral sensing by
DCs, we measured IFNa1, IFNb, and IL6 expression following
infection by HIV-1, N-MLV, EIAV in DCs transfected or not with
TRIM5a-specific siRNAs (Figure S4). HIV-1, N-MLV, and EIAV
all induced type I IFN production as already shown in Figure 6,
and knockdown of TRIM5a had no effect on IFNa1, IFNb, or IL6
expression following infection, indicating that endogenous
TRIM5a does not contribute to viral sensing by DCs. This is
concordant with our results showing that TRIM5a is sequestered
in the nucleus away from incoming retroviruses. Several groups
have shown that the pathogen recognition receptor (PRR) for
reverse transcribed DNA during retroviral infection is cGAS (Gao
et al., 2013; Lahaye et al., 2013; Rasaiyaah et al., 2013; Yoh
et al., 2015). To assess whether cGAS is responsible for innate
sensing of retroviral infection in human DCs, we transduced DCs
with short hairpin RNAs (shRNAs) targeting either cGAS or, as a
control, LacZ and monitored CD86 induction by infection. cGAS
knockdown prevented induction of CD86 expression by EIAV in
DCs, indicating that cGAS is a sensor of EIAV infection (Figure 6F).
Together, these results suggest that DCs cannot both effi-
ciently restrict and efficiently sense an incoming retrovirus. In
wild-type DCs, where TRIM5a is not present in the cytoplasm
to intercept incoming viruses, retroviruses are not restricted,
and the reverse transcribed provirus is efficiently detected by a
host sensor that triggers type I IFN production. Conversely, if
TRIM5a is forced to the cytoplasm by overexpression or inhibi-
tion of the SUMO pathway, retroviruses are restricted but are
no longer sensed, since restriction inhibits viral DNA synthesis
and all downstream replication events.
DISCUSSION
In this study, we investigated themechanism responsible for lack
of TRIM5a-mediated restriction in human and non-human pri-
mate DCs. DCs from rhesus and cynomolgus macaques, African
green monkeys, and humans were all found to be permissive to
retroviruses that are normally restricted by TRIM5a from these
species. Although TRIM5a in lymphocytes ismainly cytoplasmic,
it accumulates within NB that partly co-localize with Cajal bodies
in rhesus and human DCs. Nuclear sequestration of TRIM5a
in DCs was SUMOylation-dependent and correlated with the
lack of retroviral restriction. Forced cytoplasmic localization of
TRIM5a, either through TRIM5a overexpression or the inhibition
of SUMOylation, restored efficient restriction in DCs but abol-
ished sensing of the reverse transcribed viral genome by
cGAS. Inefficient restriction in DCs may paradoxically promoteCeffective immune control if it results in effective sensing. Thus,
the absence of efficient TRIM5a restriction in DCs might have
evolved to ensure appropriate sensing of retroviral infections
by host cell sensors.
Our results indicate that TRIM5a can be SUMO modified and
undergo nucleo-cytoplasmic shuttling in both PBLs and DCs,
but only in DCs does SUMOmodification of TRIM5a lead to Cajal
body targeting and nuclear sequestration (Figure 7). It is not
known how targeting of TRIM5a to Cajal bodies is mediated.
Although TRIM5a can be SUMO modified, we cannot exclude
that an interaction between TRIM5a SIM domains with a
SUMOylated shuttling protein is also involved. Interestingly, the
Cajal body marker coilin is both directly SUMOylated and con-
tains putative SIMs and could therefore mediate TRIM5a nuclear
targeting. In PBLs, endogenous TRIM5a remains essentially
cytoplasmic despite shuttling, and forced accumulation in
the nucleus by LMB treatment leads only to nucleoplasmic local-
ization. Further work on differences in Cajal body biology
comparing PBLs and DCs may shed light on the differential nu-
clear targeting of TRIM5a in these cells. Cajal bodies participate
in the biogenesis of spliceosomal small nuclear (snRNP) and
small nucleolar RNP (snoRNP) (Cioce and Lamond, 2005; Ma-
chyna et al., 2013; Morris, 2008), and it is unclear why TRIM5a
localizes to Cajal bodies in DCs. One possible indication comes
from the observation that TRIM5awas less SUMO-modified and
SUMO-associated in the nuclei of DCs, suggesting its targeting
to Cajal bodies may lead to its deSUMOylation and consequent
nuclear sequestration. Intriguingly, a novel SUMO isopeptidase
ubiquitin-specific protease like 1 (USPL1) was recently identified
in Cajal bodies (Schulz et al., 2012). It is also noteworthy that only
approximately one-third of nuclear TRIM5a co-localized with the
Cajal body marker coilin at any one time. Although this may be
explained by the dynamic and transient nature of Cajal bodies
or by the fact that some Cajal bodies are coilin-negative (Cioce
and Lamond, 2005; Machyna et al., 2013; Morris, 2008), it is
also possible that following SUMO-dependent targeting of
TRIM5a to Cajal bodies, deSUMOylated TRIM5a leaves Cajal
bodies and remains in the nucleoplasm. Further work will be
required to specifically test the involvement of E3 SUMO ligases
and SUMO isopeptidases in TRIM5a SUMO modification.
TRIM5a regulation by SUMOylation is likely to be a finely-tuned
mechanism since overexpression of TRIM5a led to strong accu-
mulation of TRIM5a within cytoplasmic bodies but negligible
nuclear localization, suggesting that the cellular SUMOylation
machinery had been overridden.
In DCs, nuclear sequestration of TRIM5a was associated with
efficient innate sensing of retroviral infection resulting in sub-
stantial type I interferon production. Conversely, induced cyto-
plasmic expression of TRIM5a in DCs restored restriction but
impaired viral sensing, suggesting that restriction of incoming
retroviral complexes by cytoplasmic TRIM5a prevents the
detection of one or more key viral PAMPs. Retroviral infection
of DCs may be detected by a number of cell host sensors at
different stages of the viral cycle: RIG-I-like receptors (RLR),
toll-like receptors (TLR), and DNA sensors such as IFI16 and
cGAS (Cerboni et al., 2013; Luban, 2012; Melchjorsen, 2013;
van Montfoort et al., 2014). Retroviral capsid recognition by
TRIM5a can signal production of pro-inflammatory cytokinesell Reports 14, 355–369, January 12, 2016 ª2016 The Authors 365
Figure 7. Schematic Diagram Showing the
Effect of SUMOylation on the Localization
of TRIM5a and Its Ability to Restrict Retro-
viral Infections in Primary Lymphocytes
and Dendritic Cells
When SUMOylated, TRIM5a shuttles freely be-
tween the cytoplasm and the nucleus, although in
lymphocytes its nuclear residency is brief and may
only be seen upon LMB treatment. Upon retroviral
infection of lymphocytes, cytoplasmic TRIM5a in-
tercepts incoming capsids and induces their
degradation. In DCs, SUMOylated TRIM5a is tar-
geted to Cajal bodies where it likely undergoes
deSUMOylation by isopeptidases such as USPL1.
DeSUMOylated TRIM5a remains trapped in the
nucleus and accumulates within Cajal bodies and
the nucleoplasm. Retroviral infection of DCs can
proceed unhampered in the absence of cyto-
plasmic TRIM5a, and reverse transcribed retroviral
genomes are sensed by the cytosolic sensor
cGAS, which signals interferon type I production.
Overexpression of TRIM5a, which likely over-
whelms the SUMOylation machinery, or GA treat-
ment, which prevents TRIM5a SUMOylation, both
prevent import of de novo synthesized TRIM5a to
the nucleus, restore TRIM5a-mediated restriction
and abrogate sensing by cGAS.(Pertel et al., 2011; Uchil et al., 2013). However, type I IFN
production was by far the more potent signaling outcome of
retroviral sensing in DCs. The use of the reverse transcriptase in-
hibitor TDF abolished type I IFN production following infection,
indicating that the retroviral PAMP that is recognized in infected
DCs is reverse transcribed DNA and is unlikely to be capsid.
Several groups have shown that the PRR for reverse transcribed
DNA during retroviral infection is cGAS (Gao et al., 2013; Lahaye
et al., 2013; Rasaiyaah et al., 2013; Yoh et al., 2015). Our work
confirms that cGAS is the PRR that signals sensing in human
DCs infected by N-MLV or EIAV when TRIM5a is sequestered
in the nucleus (Figure 7).
Since TRIM5a blocks reverse transcription (Stremlau et al.,
2004, 2006), efficient restriction in DCs would block innate
detection of PAMPs generated by incoming retroviruses down-
stream of reverse transcription, including reverse transcribed
viral DNA, RNA transcripts, and de novo synthesized Gag. In
addition, efficient restriction would be likely to prevent integra-
tion and presentation of endogenous viral peptides on MHC-I
molecules for CD8+ T cell priming. Both innate sensing and trig-
gering of adaptive response of retroviral infection by DCs are
crucial for an efficient immune response and the control of infec-
tion. Given that all tested DCs lacked efficient TRIM5a restric-
tion, we speculate that absence of TRIM5a restriction might
have evolved in DCs frequently exposed to retroviral infections
in order to ensure both efficient innate detection of incoming
retroviruses by host cell sensors and presentation of viral epi-
topes to cytotoxic T cells. Conversely, preservation of efficient
restriction of incoming retroviruses in lymphocytes, which we
confirmed in all tested human and non-human primates, makes
an important contribution to the defense of this cell population,
which is a key target of many retroviruses (Hatziioannou et al.,
2009; Soll et al., 2013).366 Cell Reports 14, 355–369, January 12, 2016 ª2016 The AuthorsOf note, the phenotypes described in this study for endoge-
nous TRIM5a are entirely abrogated by the expression of exog-
enous TRIM5a. Overexpression following standard transduction
protocols led to a dramatic 40-fold increase in TRIM5amRNA,
underlining the non-physiological nature of TRIM5a overexpres-
sion. The dichotomy between results obtained with endogenous
TRIM5a and overexpressed protein have been described previ-
ously (Zhang et al., 2008), confirming that caution must be exer-
cised when interpreting data based on overexpressed TRIM5a
protein. In this regard, the seeming discordance between our
study and previous work showing potent NF-kB-dependent
transcription following the sensing of retroviral capsid by TRIM5a
(Pertel et al., 2011) may be explained by the fact that the regula-
tion of TRIM5a function by SUMOylation that we describe here
was observed only with endogenous TRIM5a protein and only
in primary DCs.
In conclusion, our study reveals that the ability of TRIM5a to
restrict incoming retroviruses in human and non-human primates
is lost in DCs as a result of its SUMOylation-dependent seques-
tration in nuclear Cajal bodies. This lack of restriction allows
efficient innate sensing of incoming retroviruses by DC host
cell sensors and likely contributes to improved viral control in
the infected host. This evolutionary trade-off specific to DCs
underlines the multi-valence of DC functions at the crossroads
between innate and adaptive immunity, and the ability of DCs
to fine-tune their antigen-presenting and sensing functions to
best confront recurrent viral exposures.EXPERIMENTAL PROCEDURES
Blood Sampling
Young (3–4 years old) male cynomolgus macaques (Macaca fascicularis)
imported from Mauritius, 6- to 10-year-old pigtailed macaques (Macaca
nemestrina) originating from the Palmyre Zoo (Les Mathes, France), and 3- to
4-year-old African green monkeys (Chlorocebus sabaeus) were housed at the
Institut Pasteur non-human primates facility. Rhesus macaques (Macaca
mulatta) were housed at the CEA (Fontenay-aux-Roses). Monkeys were
tested negative for SIV, simian herpes B, filovirus, STLV-1, SRV-1, SRV-2,
measles virus, hepatitis B-HbsAg, and hepatitis B-HBcAb before inclusion
in the study. Blood sampling was conducted in accordance with guidelines
established by the French and European regulations for the care and use
of laboratory animals (Animal Welfare Assurance Number: A5476-01). Blood
from the saphenous vein was collected using heparin tubes or BD Vacutainer
CPT cell preparation tube with sodium heparin. Blood volume and bleeding
frequency were defined as a function of animal weight according to the
GIRCOR recommendations. Human buffy coats and cytopheresis rings
were obtained from the Etablissement de Sang Franc¸ais (EFS Rungis and
Ho^pital Saint-Louis).
Cells
PBMC were isolated using Ficoll (100% and 95% for human and monkey
blood, respectively) (Biochrom). Monocytes were isolated from PBMC using
adherence on plastic for 45 min. DCs were derived from monocytes following
4- to 5-day differentiation using 50 ng/ml GM-CSF (Immunotools) and 20 ng/ml
recombinant human of RM IL4 (Immunotools). PBLs were activated by treat-
ment with phytohaemagglutinin (PHA, 10 mg/ml) for 2–3 days and concanavalin
A (Con A, 5 mg/ml) (Sigma) for human and non-human primate samples,
respectively, and induced to proliferate by treatment with human recombinant
IL2 (10 ng/ml) (Sigma). The differentiation and activation phenotypes of cells
were systematically checked by phenotypic markers using flow cytometry
(Figure S1A). The human fibrosarcoma HL116 cell line carries the luciferase
gene under control of the IFN-inducible 6-16 promoter (Uze´ et al., 1994).
HL116 cells were grown in medium supplemented with HAT (hypoxanthine:
20 mg/ml, aminopterin: 0.2 mg/ml, thymidine: 20 mg/ml). P4-CCR5 are HeLa-
based cells that express CD4 and CCR5 and have Tat-inducible b-galactosi-
dase activity.
Plasmids, Vectors, Viruses
Lentiviral and retroviral vectors usedwereHIV-1 (TRIP-CMV-GFP, Pierre Char-
neau, Institut Pasteur), SIVmac239 (GAE-CAG-GFP, Franc¸ois-Loic Cosset,
ENS Lyon), EIAV-eGFP (ONY8.9, Oxford Biomedica), and N-MLV-eYFP
expressing vectors (Jonathan Stoye, MRC London). MLV-based retroviral
vectors pLPCX-TRIM5arh-HA and pLPCX-TRIM5ahu-HA were provided by J.
Sodroski (Stremlau et al., 2004). RM and human TRIM5a were fused in frame
to the mRFP fluorophore or the first 102 aa of coilin in N-ter by strand overlap
PCR. Human coilin was amplified from pENTR-COIL plasmid (Addgen
#16172). Fusion constructs were cloned within the pTRIP vector within KpnI/
XhoI restriction sites to generate the following constructs: pTRIP-CMV-
mRFP-TRIM5arh, pTRIP-CMV-mRFP-TRIM5ahu, pTRIP-CMV-COI-TRIM5arh,
and pTRIP-CMV-COI-TRIM5ahu. Viruses were SIVmac239, HIV-1 LAI,
VSV-G pseudotyped LAI, VSV-G pseudotyped NL4-3-IRES-eGFP, and R5-
tropic NL4-3-92th014.12-IRES-eGFP (Papkalla et al., 2002). Vectors and vi-
ruses were produced in HEK293T cells by calcium phosphate co-transfection
of vector/virus plasmid, Gag-Pol expressing plasmid for vectors, and pVSV-G
for pseudotyping. Supernatants were collected 48 hr post-transfection, and
vector particles were concentrated by ultracentrifugation at 22,000 rpm for
1 hr at 4C (Beckman SW41). Mus dunni tail fibroblast (MDTF) cells devoid
of TRIM5a, APOBEC3G, and tetherin restriction factors, were used to titer vec-
tors (Carthagena et al., 2008). Viral stocks were quantified by p24/p27 ELISA
(Perkin Elmer and Zeptometrix).
Transductions, Transfections
Vector transductions of PBLs and DCs were performed at MOI 0.25–5
(TU/cell) in the presence of cytokines. eGFP or eYFP expression was as-
sessed by flow cytometry or qPCR at 3–4 days post-transduction (dpt). As
a control, vectors were heat inactivated by incubation at 56C in a water
bath for 2 hr with frequent mixing prior to transduction. Plasmid and siRNA
transfections of human DCs were performed using DOTAP (Roche Molecu-
lar) at 1 mg DNA or 160 nM siRNA/0.1 3 106 DCs according to manufac-
turer’s instructions.CImaging
PBLs were cytospun onto poly-L-lysine (Sigma-Aldrich)-treated coverslips for
5 min at 500 3 g to optimize cell attachment and cytoplasmic spread. DCs
were seeded onto collagen-treated coverslips to minimize autofluorescence.
Imaging was performed using a Zen 2012 LSM700 and LSM780 confocal mi-
croscopes (Zeiss) with a Plan-Apochromat 633/NA 1.4 objective. Duolink
proximity ligation assay (PLA) was performed according to manufacturer’s in-
structions (Olink Biosciences).
Fractionation
Cytoplasmic and nuclear fractions from 4 3 106 PBLs or DCs were prepared
using NE-PER isolation kit (Pierce). Fractions were loaded onto 10% SDS-
polyacrylamide gel using equal cell equivalents rather than protein amounts.
The purity of subcellular fractionations was confirmed using tubulin and lamin
A/C for the cytoplasmic and nuclear fractions, respectively. Quantification of
protein bands was performed using ImageJ.
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